Note:Ranibizumab on blood flow density in different macular regions in ME patients secondary to ischemic and non-ischemic BRVO

DOI:

Handle Redirect
doi.org

Cite:

ZHAO, J., FENG, Z., WANG, S., FU, H., YUAN, Q., & ZHANG, Y. (2026). Ranibizumab on blood flow density in different macular regions in ME patients secondary to ischemic and non-ischemic BRVO. 26(4), 579–586. 10.3980/j.issn.1672-5123.2026.4.05

Notes:

The better prognosis in non-ischemic BRVO may be due to preserved blood flow around the fovea, allowing maintenance of photoreceptor metabolism and oxygen supply.

In ischemic cases, capillary occlusion and irreversible neuroretinal damage are already present, which may limit visual recovery even if macular edema improves.

Differences in reactivity of the deep capillary plexus (DCP):

  • In non-ischemic cases, VEGF suppression may induce a stronger physiological vasoconstrictive response
  • In ischemic cases, the vasculature is already damaged, resulting in a blunted response

#BRVO #Ranibizumab #OCTA

Comments

Copied title and URL